Pharvaris (NASDAQ:PHVS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pharvaris (NASDAQ:PHVS) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Other analysts have also recently issued research reports about the company. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $16.00 to $27.00 in a report on Thursday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. JMP Securities reduced their price objective on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Finally, Morgan Stanley raised their price target on shares of Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.57.

Pharvaris Trading Up 2.3%

PHVS opened at $25.39 on Friday. Pharvaris has a 12 month low of $11.51 and a 12 month high of $26.33. The company has a market cap of $1.33 billion, a PE ratio of -7.91 and a beta of -2.78. The company has a 50 day moving average of $23.37 and a 200 day moving average of $20.99.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. Research analysts forecast that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the stock. TD Asset Management Inc raised its position in shares of Pharvaris by 27.4% during the 2nd quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after buying an additional 21,388 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Pharvaris in the second quarter valued at $57,000. Palumbo Wealth Management LLC raised its position in Pharvaris by 3.2% during the second quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after purchasing an additional 447 shares in the last quarter. Deutsche Bank AG lifted its stake in Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock worth $442,000 after purchasing an additional 10,006 shares during the last quarter. Finally, Foresite Capital Management IV LLC boosted its holdings in shares of Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after purchasing an additional 368,000 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.